In the Spotlight...

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas

Labiano et al. showed that in mice with diffuse midline glioma (DMG), intratumoral co-administration of the Delta-24-RGD oncolytic virus and agonist CD40 antibodies extended survival and induced compl...

A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis

Qian and Ma et al. fused TFF2, a partial CXCR4 agonist, with murine serum albumin (MSA) to develop TFF2–MSA peptides that restore anti-PD-1 sensitivity in syngeneic gastric cancer (GC) tumor models. ...

Regulatory T cells define affinity thresholds for CD8+ T cell tumor infiltration

Mohsen et al. showed that a low-affinity LCMV p33-derived A4Y peptide linked to a bacteriophage Qβ virus-like particle induced a robust and specific T cell response, but showed limited cross-reactivit...

Synthetic biology-driven induction of mature TLS formation enhances antitumor immunity in colorectal cancer

Mi et al. developed an attenuated Salmonella typhimurium strain that harbored a quorum-sensing synchronized lysis circuit (SLC) and overexpressed LIGHT. Intragastric SLCVNP20009 treatment colonized tu...

Previous Digests

PSGL-1: a novel immune checkpoint for phagocytosis

June 25, 2025

Tumor cells can evade immune detection through a wide range of mechanisms, not all of which are fully understood. In recent work by Zhong and Wang et al., P-selectin glycoprotein ligand 1 (PSGL-1) – a known molecule involved in...

​​Dimming IFN signaling to brighten CAR-T persistence and efficacy

June 18, 2025

While CAR T cell therapy has shown great success in hematological cancers, relapses may occur, and the therapy has so far shown limited efficacy in solid tumors. Based on their previous data, which showed that genetic deletion of IFNγ...

A new off-the-shelf CAR T cell product made from iPSCs

June 11, 2025

CAR T cell therapies are well known for their potent capacity for killing antigen-expressing target cells. However, they are often hindered by factors in solid tumors and by challenges related to the development of an autologous T cell product...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Llambi

Gaelle Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.